Time to bite the biotech bullet

18-Mar-2008

The UK pharmaceutical industry could make more rapid progress in exploiting the potential of biotechnology if the scientists were better informed about the procedures for taking drugs to clinical trial and approval, and if regulatory affairs staff knew more about the science. That's the view of Professor Sandy Primrose, a recognised authority on biotech industries.

"The technical decisions that have to be taken during research and development would also have more commercial relevance if the scientists had a better understanding of the regulatory process," argues Professor Primrose. "It would also improve job satisfaction if researchers had a clearer understanding of why they have to perform certain duties in order to get a concept through to the stage of clinical trials. Likewise, the regulatory affairs people would benefit hugely from knowing more of the science behind the products that they are expected to bring to market."

Professor Primrose was speaking at the launch of a new course from RSSL Pharma Training, which is designed to address the central challenges involved in exploiting biotechnology in pharmaceuticals and diagnostics. The one-day course will present an overview of the market, address key aspects of production and analysis, and discuss all aspects of the regulatory framework. It will give all delegates a thorough grounding in the process from start to finish.

"We see this course is a vital addition to our training portfolio," says Lyndsey Wright, Manager of RSSL Pharma Training. "We have been aware for some time that people with different roles are largely unaware of each other's demands and constraints. This course, and others we have in the pipeline, will go a long way to filling the gaps in their knowledge, and we believe it will help many companies to make faster progress in bringing biotech products to market."

https://www.bionity.com/en/news/79731/time-to-bite-the-biotech-bullet.html